Search Results for: Research
On May 12-13, the 4th Gnosis Vitamin K2 Scientific Advisory Committee (K2SAC) meeting brought together leading experts in Greece to explore the latest breakthroughs in vitamin K2 research and innovation.
On May 12-13, the 4th Gnosis Vitamin K2 Scientific Advisory Committee (K2SAC) meeting brought together leading experts in Greece to explore the latest breakthroughs in vitamin K2 research and innovation.
The Gnosis Vitamin K2 Scientific Advisory Committee (K2SAC), an international group of leading researchers dedicated to advancing the science of vitamin K2, held its fourth meeting on May 12-13th, 2025, in Greece. Chaired by Professor Leon Schurgers (Maastricht University), the committee plays a key role in guiding scientific dialogue and shaping research priorities around vitamin K2‘s clinical potential.
Dr. Stefanos Roumeliotis, Head Academic Researcher, 2nd Department of Nephrology, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, Greece hosted the meeting in his hometown of Thessaloniki, where he not only presented exciting new research and introduced his clinical colleagues, but also gave the committee a taste of authentic Greek food.
Dr. Kimmo Makinen, Gnosis Head of Scientific Affairs, shared key strategic insights with crucial direction as it might help shape the vision for future research priorities and clarified main areas of interest for the next five years.
The Scientific Session highlighted cutting-edge, unpublished research, featuring contributions from leading experts in the field including Prof. Schurgers, Dr. Sola Bahous , and Dr. Stefanos Roumeliotis.
A session dedicated to early-career researchers offered fresh perspectives, including an outstanding presentation by industrial PhD student Rudolf Bittner (Gnosis by Lesaffre/Maastricht University), who shared post-hoc findings from the MenaQ7® one-year clinical study. “Sharing these findings with leading experts in the field was a valuable opportunity to spark dialogue around the future potential of this important nutrient” he noted.
The meeting also explored practical dimensions of vitamin K2 application.
“Marketing session was concentrated on market-oriented perspectives, exploring how science can be translated into consumer-facing messages and product strategies.” concluded Kimmo Makinen.
Altogether, the meeting highlighted both the growing clinical evidence and the dynamic pipeline of new research shaping the future of vitamin K2.
Do you need more information about Vitamin K2 or have any outstanding questions? Please do not hesitate to contact us; our expert team will happily answer!
>> CONTACT US<<
In a significant step towards enhancing the scientific understanding of vitamin K2, Gnosis recently sponsored the 7th Osteoporosis Congress in Padova, Italy. This event, supported by the Italian Ministry of Health, gathered renowned experts in nephrology, osteoporosis, and bone health.
In a significant step towards enhancing the scientific understanding of vitamin K2, Gnosis recently sponsored the 7th Osteoporosis Congress in Padova, Italy. This event, supported by the Italian Ministry of Health, gathered renowned experts in nephrology, osteoporosis, and bone health.
The congress was chaired by Dr. Maria Fusaro, a Medical Doctor and respected researcher known for her extensive work on vitamin K. During the event, Dr. Fusaro emphasized the critical role of vitamin K2, such MenaQ7®, in supporting bone health.
We are thrilled to have been a part of this prestigious event. Our sponsorship of the 7th Osteoporosis Congress highlights our commitment to advancing the scientific understanding of vitamin K2 and its significance to overall health.
One of the congress’s key highlights was Dr. Fusaro’s announcement of a long-term project to identify the most effective forms of vitamin K within the existing molecules pool. This initiative is expected to provide valuable insights into the efficacy and applications of different vitamin K variants.
The congress also revealed a strong interest among attending physicians in learning more about vitamin K2. Many doctors were not fully aware of this specific nutrient but showed eagerness to understand its importance and potential benefits.
The enthusiasm and curiosity expressed by the doctors at the event were truly encouraging. It reinforces the need for continued education and research in vitamin K2, and we are excited to explore potential collaborations with Dr. Fusaro and other leading experts in this area.
Gnosis‘s participation in the 7th Osteoporosis Congress is part of its efforts to promote awareness and understanding of vitamin K2 among healthcare professionals and the general public. Gnosis aims to advance bone health and overall well-being by sponsoring such events and supporting cutting-edge research.
Download our MenaQ7® brochure to discover more!
>> DOWNLOAD<<
Discover how the latest research is driving the potential for Vitamin K2 on human health. Mark your calendar for an insightful webinar hosted by Nutraingredients, featuring Gnosis K2 experts. Join us Aug 31st at 7 pm CET – 1 pm EST – 10 am PST! Beyond Bones and Heart: New Avenues for Vitamin K2 … Continue reading Don’t Miss Our Upcoming Webinar: How Research Shape the Future of the Vitamin K2 Category
Discover how the latest research is driving the potential for Vitamin K2 on human health. Mark your calendar for an insightful webinar hosted by Nutraingredients, featuring Gnosis K2 experts.
Join us Aug 31st at 7 pm CET – 1 pm EST – 10 am PST!
Beyond Bones and Heart: New Avenues for Vitamin K2
The Vitamin K2 category has long been established on a foundation of clinical evidence, with MenaQ7® leading the way in confirming its safe and effective health benefits across all age groups. As research continues to unfold, the known mechanisms of Vitamin K2, particularly on cardiovascular health, reveal promising associations with cognition, metabolic health, inflammation, and more. Our upcoming webinar will provide unique insights into ongoing studies and future research surrounding this essential nutrient, uncovering its next possible indications and untapped potential within the market.
Leading Experts in Vitamin K2 Research
Get valuable insight from Gnosis’s astute speakers: Dr. Stacey Smith, DC, Marketing & Communications Manager, and Dr. Hogne Vik, MD, PhD, MBA, Medical and Scientific Advisor. Together, their substantial knowledge will guide you through the dynamic and ever-expanding landscape of Vitamin K2, unveiling links to different areas of health, and the numerous opportunities within the category.
Embarking on a Journey Towards Innovation
Beyond its well-established benefits for heart and bone health, Vitamin K2 research is venturing into new territories of human health. Our speakers will present a magnifying glass into the future of the Vitamin K2 category, founded on the clinical validation of MenaQ7®. Further, the cutting-edge advancements in K2 solutions offer innovative formulations in new sought-after finished product dose forms, enhancing the value of supplements designed to support foundational health throughout all stages of life.
Our webinar is an opportunity to gain exclusive insights into the transformative potential of Vitamin K2 and its profound impact on human health. Equipped with this knowledge, you will be set to make informed decisions and drive the future of your Vitamin K2 Portfolio.
> Sign up now !
Gnosis by Lesaffre (Gnosis) is eager to share new insights highlighting most women are at greater risk of developing heart disease than previously thought, as new studies have suggested that reproductive factors and menopause factors are implicated in the development of adverse cardiovascular conditions. While the findings are alarming, it punctuates the importance of Gnosis’ … Continue reading New Research Substantiates Women’s Need for Vit K2 to Protect Heart Health
Gnosis by Lesaffre (Gnosis) is eager to share new insights highlighting most women are at greater risk of developing heart disease than previously thought, as new studies have suggested that reproductive factors and menopause factors are implicated in the development of adverse cardiovascular conditions. While the findings are alarming, it punctuates the importance of Gnosis’ clinically validated MenaQ7® Vitamin K2 as MK-7.
One observational study has concluded that an earlier first birth, a higher number of births, and menarche at younger ages are linked to a higher risk of cardiovascular conditions in women. The researchers, from the Imperial College London’s National Heart & Lung Institute, performed a comprehensive analysis of reproductive factors specific to women and their links to a range of cardiovascular diseases, including atrial fibrillation (irregular heart rate), coronary heart disease, heart failure, and stroke.
Using a technique called Mendelian Randomization, the researchers revealed an association between the genes that predict reproductive factors and the risk of multiple cardiovascular diseases. According to British Heart Foundation data, coronary heart disease kills more than twice as many women as breast cancer in the UK.[1]
“Women are often mischaracterized as being at low risk for cardiovascular disease, leading to delays in diagnosis. Even when they are diagnosed, they tend to receive less targeted treatment than men,” states Dr. Maddalena Ardissino, of the National Heart and Lung Institute at Imperial College, London, and lead study author.
Her colleague, Dr. Fu Siong Ng, senior author of the study, noted, “Many of the previous studies on cardiovascular disease have focused on men, but our research shows that there are sex-specific factors that influence the risk for women.”
Earlier research has established a causative link between menopause and increased risk of cardiovascular disease. In their review, El Khoudary et al. highlight that women transitioning through menopause experience “their arteries become more vulnerable to disease, getting thicker and stiffer.” They note that reported findings “underline the significance of MT [menopause transition] as a time of accelerating CVD risk, thereby emphasizing the importance of monitoring women’s health during midlife, a critical window for implementing early intervention strategies to reduce CVD risk.”[2]
One such strategy is simple and proven: supplementing with vitamin K2 menaquinone-7 (MK-7). In two groundbreaking human clinical trials[3,4], daily supplementation with 180 mcg of MenaQ7â Vitamin K2 as MK-7 was found to protect cardiovascular function in women. Namely, activating the K-dependent protein Matrix Gla Protein (MGP) led to improved arterial stiffness in the supplement groups.
“Gnosis by Lesaffre works with world-renowned researchers to confirm the safe and effective health benefits of MenaQ7 Vitamin K2 as MK-7,” says Jean-Francois Jeanne, Substantiation & Applications Team Manager. “Elucidating the important mechanism of activating K-dependent proteins, including osteocalcin and MGP, was foundational to that work.
“Supplementing with K2 as MK-7 is a simple, natural tool for women to protect their heart and cardiovascular system,” he continues. “As new research emerges that confirms the high risk of heart disease in women, the greater the need for sustainable, natural and inexpensive tools such as vitamin K2 as MenaQ7 for protecting the cardiovascular structure and function in women as they age.”
References
1 Ardissino M, et al. “Sex‐Specific Reproductive Factors Augment Cardiovascular Disease Risk in Women: A Mendelian Randomization Study. Journal of the American Heart Association, 2023
2 El Khoudary SR, et al. “Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association” Circulation 2020 142(25):e506-e532
3 Vermeer C and Vik H, “Effect of Menaquinone-7 (vitamin K2) on vascular elasticity in healthy subjects: results from a one-year study” Vascul Dis Ther, 2020 5:1-4.
4 Knapen MHJ, et al. “Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomised clinical trial” Thrombosis and Haemostasis 2015 113.5